Continuous Glucose Monitoring Systems Market
The Global CGMS Market $589 million in 2015, and is projected to reach $6,238 million by 2022, registering a CAGR of approximately 39.9% from 2016 to 2022.
Real-time continuous glucose monitoring is of utmost importance across all age groups to manage diabetes effectively. Continuous glucose monitoring system (CGMS) enables effective managing of blood glucose levels by providing trend data as well as alarms for the fluctuations in glucose levels.
Diabetes, a chronic lifestyle disease, is classified into type 1 and type 2 diabetes. In type 1 diabetes, the pancreas is unable to produce sufficient or requisite amount of insulin hormone, which is required for the breakdown of glucose. It is prevalent in children or young adults and as per the global estimates of International Diabetes Federation (IDF), in 2015, Type 1 diabetes has affected around 542,100 children in the age group below 15 years. Whereas, in type 2 diabetes, the pancreas produce insulin, but the cells do not respond and/or lack the ability to uptake the insulin available in the blood stream. It is the most prevalent type of diabetes, affecting around 8% share of the global population in the age group of 2079 years, which accounts for more than 95% of all types of diabetes.
About 19% of the global healthcare expenditure on diabetes was spent on low- and middle-income groups, which comprise a significant proportion of diabetic patients. On an average, about $5,374 - $9,641 per person was spent by individuals belonging to high-income countries, whereas about $401 - $688 was spent in low- and middle-income countries. It is observed that the U.S. spent about $320 billion of its health budgets for diabetes management, whereas China, with the most number of diabetes population spent about $51 billion on diabetes. The combined healthcare cost of three leading countries, namely U.S., Germany, and China with respect to the prevalence of diabetes is almost 60% of the global healthcare expenditure on diabetes. It can be inferred that people living in low- and middle-income countries spend more on diabetes management as compared to the high-income groups.
This disparity in diabetes healthcare expenditure among high-, low-, and middle-income countries is due to lack of access to health insurance and government-provided medical services.
GLOBAL FINANCIAL BURDEN OF DIABETES, BY GEOGRAPHY, 2015
Furthermore, according to some reports and healthcare experts, about 193 million people, or close to half (46%) of all people with diabetes are undiagnosed, which has led to adverse and costly implications. Thus, it is evident that diabetes management is imperative across all geographical regions and age cohorts in the age group of 5079 years. Measuring/monitoring and managing glucose levels are primary tasks in diabetes management, which can be conducted using glucose monitoring devices.
UNDIAGNOSED PATIENT POPULATION OF DIABETES, 2015 (MILLION)
This can be attributed to the enhanced technological innovations, such as higher convenience offered by CGMS over self-monitoring blood glucose (SMBG) devices, and the detection of hypo- and hyperglycemic events by CGMS. Increase in health awareness and affordability of devices in the developed and developing economies have contributed towards the market growth.
GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET SEGMENTATION
The global continuous glucose monitoring (CGM) systems market is segmented based on component, end user segment, demographics, and geography. Based on the frequency of use, the CGM components market is sub segmented into sensors, transmitters & receivers, and integrated insulin pumps. Transmitters & receivers coupled with sensors are known as standalone CGM systems, which are preinstalled by OEMs. Sensors are disposable components, which need to be replaced after every 57 days. The report presents data on integrated insulin pumps segment includes insulin pumps integrated with the CGM system, and not individual insulin pumps. Based on end user segment, the market is classified into diagnostics/clinics, ICUs, and home healthcare settings. Based on demographics, the market is divided into child population and adult population. Child population segment includes population in the age group of up to 14 years, whereas adult segment includes population in the age group of above 14years. By geography, this market is studied with respect to four major regionsNorth America (U.S., Canada, and Mexico), Europe (UK, Germany, France, Spain, Italy, Netherlands, Norway, Sweden, Denmark, Finland, and others), Asia-Pacific (Japan, China, India, Australia, South Korea, and others), and LAMEA (Brazil, Venezuela, Saudi Arabia, South Africa, Argentina, and others). The report includes the revenue generated from the sales of these aforementioned categories.
The global CGMS market is still in the developing phase, with CGMS technology being the core sub-set in the value chain of diabetes monitoring devices. Therefore, product development is the key strategy adopted by market players, followed by collaboration. For instance, on September 2016, Abbott received FDA approval for Freestyle Libre Pro System. This system can provide patients ambulatory glucose profile to healthcare professionals.
Acquisition is another key strategy that has been adopted by key companies. Due to the presence of numerous small-sized to mid-sized companies, the larger companies acquire smaller and emergent companies to curb the competition and increase their revenue. For instance,on May 2, 2016, DexCom acquired Nintamed, a distributor company with presence in Switzerland, Germany, and Austria to improve the global access to CGM technologies.
The key players profiled in the report include Abbott Laboratories, Dexcom, Inc., Echo Therapeutics, Inc., GlySens Incorporated, Johnson & Johnson, Medtronic plc, Senseonics Holdings, Inc., and F. Hoffmann-La Roche Ltd. Other players in the CGMS market include (profiles not included in the report) include AgaMatrix, Inc., Arkray USA, Inc., Glucovation, GlySure, OrSense, GlySure, and Pinnacle Technology.
GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET REVENUE, BY GEOGRAPHY
The untapped regions such as Asia-Pacific, Africa, and Latin America are anticipated to emerge as a lucrative market, owing to the presence of large pool of diabetic patients, which makes them highly opportunistic markets for investment, and rise in disposable incomes. Moreover, in highly populous countries, about 8090% of the people with diabetes remain undiagnosed, whereas it is only 30% in high-income countries. The aforementioned factors are expected to boost the growth of the CGMS market in the Asia-Pacific and LAMEA region.
ARGENTINACONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 20142022 ($THOUSAND)
Argentina CGMS devices market is projected to grow at a high CAGR of 43.9% during the forecast period, generating revenue of $3,818 thousand by 2022. The lack of awareness and issues pertaining to price constraints could restrain the market growth. However, supportive government policies, such as spreading awareness and funding or reimbursement for CGM devices would boost the growth of the CMGS market in Argentina.
KEY BENEFITS FOR STAKEHOLDERS:
- The report provides an extensive analysis of the current trends and highlights the market potential from 2014 to 2022, in terms of value.
- The market scenario is comprehensively analyzed with respect to the components, demographics, and end user.
- Comprehensive analysis of the patents is provided to determine the prevailing opportunities.
- Recent developments, key manufacturers, and market shares are listed in this report to analyze the competitive scenario of the market.
- In-depth analysis of the market based on geography gives an understanding of the regional market, which assists in strategic business planning.
CGM MARKET KEY SEGMENTS:
The CGMS market is segmented based on component, end user segment, end user demographics, and geography (country-level analysis).
- Transmitters & Receivers
- Integrated Insulin Pumps
- Child Population (=14 years)
- Adult Population (>14 years)
By End User
- Home Healthcare
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA